Skip to main content

Table 2 Univariate Cox regression analysis of overall and recurrence-free survival in 153 HCC patients

From: Multilevel regulation of RUVBL2 expression predicts poor prognosis in hepatocellular carcinoma

Variables Overall survival Relapse-free survival
P-value HR 95% CI P-value HR 95% CI
Nuclear RUVBL2 (strong vs. Neg + weak) 0.0064 2.03 1.22–3.37 0.1522 1.42 0.88–2.31
Cytoplasmic RUVBL2 (strong vs. Neg + weak) 0.0862 1.47 0.95–2.27 0.0088 1.71 1.44–2.56
Age (> 60 vs. ≤ 60) 0.7896 1.06 0.68–1.66 0.6266 1.11 0.73–1.67
Sex (female vs. male) 0.2357 0.54 0.20–1.49 0.0713 0.40 0.15–1.08
Family history (yes vs. no) 0.0943 0.66 0.41–1.07 0.0590 0.65 0.42–1.02
Symptom presentation (yes vs. no) 0.0864 1.46 0.95–2.26 0.1258 1.36 0.92–2.03
Drinking (yes vs. no) 0.7888 0.94 0.62–1.44 0.7493 0.94 0.65–1.37
HBsAg (positive vs. negative) 0.1842 0.71 0.42–1.18 0.4802 0.84 0.51–1.37
Anti-HCV (positive vs. negative) 0.5942 1.23 0.57–2.68 0.7104 1.15 0.56–2.37
Cirrhosis (moderate + severe vs. w/o + mild) 0.0545 1.52 0.99–2.34 0.1645 1.32 1.89–1.96
CEA (> 5 vs. ≤ 5) 0.3999 1.40 0.64–3.04 0.3377 1.40 0.70–2.78
ALP (aberrant vs. normal) 0.9062 0.96 0.50–1.84 0.3606 1.29 0.75–2.24
AFP (> 20 vs. ≤ 20) 0.6581 1.10 0.71–1.70 0.8061 1.05 0.71–1.56
Differentiation grade (poor vs. well + moderate) 0.0363 1.30 1.02–1.66 0.0409 1.27 1.01–1.60
Tumor size (> 5 cm vs. ≤ 5 cm) 0.0459 1.57 1.01–2.44 0.0107 1.69 1.13–2.53
Multinodules (yes vs. no) 0.0853 1.56 0.94–2.58 0.1152 1.46 0.91–2.36
Tumor-infiltrating lymphocytes (yes vs. no) 0.7268 1.09 0.67–1.76 0.4599 1.18 0.76–1.84
Liver capsule invasion (yes vs. no) 0.4503 0.84 0.54–1.31 0.7892 0.95 0.63–1.42
Carcinoma cell embolus (yes vs. no) 0.0080 2.19 1.23–3.90 0.0003 2.66 1.56–4.53
TNM staging (III + IV vs. I + II) < 0.0001 1.65 1.25–2.19 0.0014 1.54 1.18–2.00
BCLC staging (2 + 3 vs. 0 + 1) < 0.0001 2.45 1.49–4.04 0.0023 2.10 1.30–3.38